DrugPatentWatch Database Preview

Details for Patent: 10,357,616

« Back to Dashboard

Which drugs does patent 10,357,616 protect, and when does it expire?

Patent 10,357,616 protects OZEMPIC and SAXENDA and is included in two NDAs.

This patent has fifteen patent family members in eleven countries.

Summary for Patent: 10,357,616

Title:	Injection device with an end of dose feedback mechanism
Abstract:	An injection device with a dose delivering mechanism being adapted to provide a non-visual, e.g. audible and/or tactile, feedback signal when a set dose has been at least substantially injected. A first and a second part of the injection device are adapted to perform a relative rotational movement with respect to each other. The relative rotational movement causes at least two parts of the injection device to abut or engage, and this abutment or engagement causes the non-visual feedback signal to be generated. A very distinct and precise feedback is provided as compared to prior art axial solutions because the generation of the feedback signal is initiated by the relative rotational movement. Feedback signal may be generated by a change in a rotational velocity of at least one part, e.g. by changing the pitch of a threaded portion or by engaging a non-rotating part and a rotating part, thereby causing the non-rotating part to start rotating. May alternatively be generated by building up and releasing a tension. The injection device is suitable for injecting insulin.
Inventor(s):	Moller; Claus Schmidt (Fredensborg, DK), Radmer; Bo (Hilleroed, DK), Nielsen; Lars Ulrik (Virum, DK), Enggaard; Christian Peter (Vejby, DK)
Assignee:	Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:	15/815,976
Patent Claim Types: see list of patent claims	Use; Delivery; Device;

Drugs Protected by US Patent 10,357,616

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novo	OZEMPIC	semaglutide	SOLUTION;SUBCUTANEOUS	209637-001	Dec 5, 2017		RX	Yes	Yes			Y
Novo	SAXENDA	liraglutide recombinant	SOLUTION;SUBCUTANEOUS	206321-001	Dec 23, 2014		RX	Yes	Yes			Y

Foreign Priority and PCT Information for Patent: 10,357,616

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	05075187	Jan 25, 2005

International Family Members for US Patent 10,357,616

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2006208606
Brazil	PI0607012
Canada	2595323
China	101107032
Denmark	1877119